Ipsat therapies
WebApr 5, 2005 · Helsinki, Finland (5 April 2005) -- Ipsat Therapies, a Finnish biopharmaceutical company with a novel approach to fighting hospital acquired infections and antibiotic resistance, today announced positive Phase IIa clinical trial data for its lead product, P1A. The product is designed to inactivate beta-lactam antibiotics in the lower intestinal ... WebIpsat Therapies Ltd. Ipsat Therapies Ltd. United States C Corporation No tags have been applied so far. Sign in to add some. Profile People (0) Documents (0) Dockets (0) Attorneys (0) Markets (0) Patents (1) Trademarks (0) Payments (0) Related (0)
Ipsat therapies
Did you know?
http://content.stockpr.com/syntheticbiologics/db/193/451/presentation/ICETAR+Talk+25June15_Final.pdf WebBiotie Therapies Finland Listed Biotie (Turku, Finland) is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric …
WebHELSINKI, June 8 /PRNewswire/ -- Ipsat Therapies announced today that oral P1A beta-lactamase met all end-points and provided protection for the normal gastrointestinal … WebFinland. Listed. Biotie (Turku, Finland) is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, bipolar disorder, addictions and drug dependence) and inflammatory diseases (rheumatoid arthritis ...
WebIpsat Therapies. Manufacturing · Canada · <25 Employees . Ipsat Therapies Ltd is a private Finnish biotechnology company developing its proprietary IPSAT™ ("Intestinal Protection … WebJun 19, 2007 · Applicant: IPSAT Therapies Oy Inventors: Pertti Koski, Tapio Korkolainen, Kristiina Raatesalmi MODIFIED BETA-LACTAMASE AND METHOD FOR ITS PREPARATION. Publication number: 20090181004 Abstract: The invention relates to targeted post translational modifi-cation of metallo-beta-lactamase by truncation and inser-tion of a …
WebOct 25, 2007 · Ipsat Therapies Ltd is a private company focusing on the development of products in the anti-infective field. Ipsat´s focus is primarily on the development of products for the prevention of antibiotic resistance, antibiotic-associated diarrhea and hospital associated infections.
WebOct 31, 2007 · Ipsat Therapies Oy obtained positive data from a Phase IIb clinical trial of its adjunctive penicillin antibiotic therapy P1A, a recombinant beta lactamase enzyme intended to minimize disruption of the normal bacterial flora of the large intestine caused by the presence of unabsorbed drug. The drug candidate attained its two primary endpoints ... highfield adresseWebDec 26, 2014 · Helsinki, Finland(24 th January 2006) -- IpsatTherapies, a Finnish biopharmaceutical company with a novel approach tofighting hospital acquired infections andantibiotic resistance today announced that it closed a €3 million private placement with InnovationsKapital, Stockholm, Sweden. highfield advisoryWebOct 25, 2007 · Ipsat Therapies Ltd is a private company focusing on the development of products in the anti-infective field. Ipsat´s focus is primarily on the development of … highfield aetWebMar 23, 2009 · The active ingredient of Ipsat P1A capsule is P1A protein. P1A protein is a recombinant class A β-lactamase with a molecular mass of 29 kDa which is capable of hydrolyzing penicillin, aminopenicillins (e.g., ampicillin), and … highfield administrator loginWebThe IPSAT is not a new assessment. It is a process designed to help you gain the maximum value from a bundle of assessments. We use a powerful self authoring process to help you write five short identity statements that explain how your personality, strengths, skills, values and passions work together in real life. One-on-one Virtual Coaching highfield act awareness e learningWebThis phase IIb trial investigated the effects of oral P1A [Ipsat P1A] on gastrointestinal microflora in hospitalised patients treated with IV ampicillin for Phase IIb trial investigating the effects of P1A on gastrointestinal microflora in hospitalised patients treated with IV ampicillin for serious upper- and lower respiratory tract infections ... highfield act e learningWebCraniosacral Therapy (developed by Dr. John Upledger) works with your body’s craniosacral system to support and nourish the central nervous system – improving health and well … highfield adventure